Alan Cass

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4274127/publications.pdf

Version: 2024-02-01

50276 19190 14,302 118 46 118 citations h-index g-index papers 119 119 119 14501 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Using web conferencing to engage Aboriginal and Torres Strait Islander young people in research: a feasibility study. BMC Medical Research Methodology, 2021, 21, 172.	3.1	4
2	Chronic kidney disease and socio-economic status: a cross sectional study. Ethnicity and Health, 2020, 25, 93-109.	2.5	15
3	EXamining ouTcomEs in chroNic Disease in the 45 and Up Study (the EXTEND45 Study): Protocol for an Australian Linked Cohort Study. JMIR Research Protocols, 2020, 9, e15646.	1.0	9
4	Incorporating indigenous knowledge in health services: a consumer partnership framework. Public Health, 2019, 176, 159-162.	2.9	14
5	Sex and mortality in septic severe acute kidney injury. Journal of Critical Care, 2019, 49, 70-76.	2.2	15
6	Patient-reported barriers and outcomes associated with poor glycaemic and blood pressure control in co-morbid diabetes and chronic kidney disease. Journal of Diabetes and Its Complications, 2019, 33, 63-68.	2.3	9
7	Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection. Nephrology Dialysis Transplantation, 2018, 33, gfw396.	0.7	6
8	Renal replacement therapy intensity for acute kidney injury and recovery to dialysis independence: a systematic review and individual patient data meta-analysis. Nephrology Dialysis Transplantation, 2018, 33, 1017-1024.	0.7	32
9	High Baseline Levels of Tumor Necrosis Factor Receptor 1 Are Associated With Progression of Kidney Disease in Indigenous Australians With Diabetes: The eGFR Follow-up Study. Diabetes Care, 2018, 41, 739-747.	8.6	32
10	Impact of CKD on Household Income. Kidney International Reports, 2018, 3, 610-618.	0.8	25
11	Trajectories of eGFR decline over a four year period in an Indigenous Australian population at high risk of CKD-the eGFR follow up study. Clinical Biochemistry, 2018, 53, 58-64.	1.9	3
12	Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation. Kidney International, 2018, 93, 1000-1007.	5.2	32
13	Higher versus Lower Continuous Renal Replacement Therapy Intensity in Critically ill Patients with Liver Dysfunction. Blood Purification, 2018, 45, 36-43.	1.8	12
14	Outcomes after Angiography with Sodium Bicarbonate and Acetylcysteine. New England Journal of Medicine, 2018, 378, 603-614.	27.0	399
15	Disparity of access to kidney transplantation by Indigenous and nonâ€Indigenous Australians. Medical Journal of Australia, 2018, 209, 261-266.	1.7	38
16	A Trial of Extending Hemodialysis Hours and Quality of Life. Journal of the American Society of Nephrology: JASN, 2017, 28, 1898-1911.	6.1	62
17	Representativeness of Honeypot Trial Participants to Australasian PD Patients. Peritoneal Dialysis International, 2017, 37, 516-522.	2.3	3
18	Effect of Fish Oil Supplementation and Aspirin Use on Arteriovenous Fistula Failure in Patients Requiring Hemodialysis. JAMA Internal Medicine, 2017, 177, 184.	5.1	77

#	Article	IF	Citations
19	Comparison of creatinine and cystatin C based eGFR in the estimation of glomerular filtration rate in Indigenous Australians: The eGFR Study. Clinical Biochemistry, 2017, 50, 301-308.	1.9	17
20	Bilirubin concentration is positively associated with haemoglobin concentration and inversely associated with albumin to creatinine ratio among Indigenous Australians: eGFR Study. Clinical Biochemistry, 2017, 50, 1040-1047.	1.9	6
21	Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy. JAMA - Journal of the American Medical Association, 2017, 318, 432.	7.4	376
22	Self-management in patients with diabetes and chronic kidney disease is associated with incremental benefit in HRQOL. Journal of Diabetes and Its Complications, 2017, 31, 427-432.	2.3	24
23	Organ Transplantation in Australia. Transplantation, 2017, 101, e345-e346.	1.0	11
24	Preferences for Policy Options for Deceased Organ Donation for Transplantation. Transplantation, 2016, 100, 1136-1148.	1.0	21
25	Femoral Access and Delivery of Continuous Renal Replacement Therapy Dose. Blood Purification, 2016, 41, 11-17.	1.8	26
26	Facilitating engagement through strong relationships between primary healthcare and Aboriginal and Torres Strait Islander peoples. Australian and New Zealand Journal of Public Health, 2016, 40, 535-541.	1.8	48
27	The health-related quality of life of Indigenous populations: a global systematic review. Quality of Life Research, 2016, 25, 2161-2178.	3.1	50
28	Progression of Kidney Disease in Indigenous Australians: The eGFR Follow-up Study. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 993-1004.	4.5	23
29	The Validity of Left Ventricular Mass as a Surrogate End Point for All-Cause and Cardiovascular Mortality Outcomes in People With CKD: A Systematic Review and Meta-analysis. American Journal of Kidney Diseases, 2016, 68, 554-563.	1.9	51
30	The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: Sub-study of the HERO trial. Redox Report, 2016, 21, 14-23.	4.5	8
31	Risk Factors for Stroke in People with End-Stage Kidney Disease: A Cohort Study. Cerebrovascular Diseases, 2016, 42, 428-438.	1.7	8
32	Getting it Right: study protocol to determine the diagnostic accuracy of a culturally-specific measure to screen for depression in Aboriginal and/or Torres Strait Islander people. BMJ Open, 2016, 6, e015009.	1.9	14
33	Epidemiology of RBC Transfusions in Patients With Severe Acute Kidney Injury. Critical Care Medicine, 2016, 44, 892-900.	0.9	9
34	Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP). American Journal of Kidney Diseases, 2016, 68, 371-380.	1.9	57
35	Impact of Educational Attainment on Health Outcomes in Moderate to Severe CKD. American Journal of Kidney Diseases, 2016, 67, 31-39.	1.9	42
36	Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the StudyÂofÂHeartÂand Renal Protection (SHARP). American Journal of Kidney Diseases, 2016, 67, 576-584.	1.9	19

#	Article	IF	CITATIONS
37	Do polypills lead to neglect of lifestyle risk factors? Findings from an individual participant data meta-analysis among 3140 patients at high risk of cardiovascular disease. European Journal of Preventive Cardiology, 2016, 23, 1393-1400.	1.8	14
38	Effectiveness of fixed dose combination medication (â€~polypills') compared with usual care in patients with cardiovascular disease or at high risk: A prospective, individual patient data meta-analysis of 3140 patients in six countries. International Journal of Cardiology, 2016, 205, 147-156.	1.7	103
39	Associations of serum adiponectin with markers of cardio-metabolic disease risk in Indigenous Australian adults with good health, diabetes and chronic kidney disease. Obesity Research and Clinical Practice, 2016, 10, 659-672.	1.8	6
40	The \hat{l}^2 -Blocker to Lower Cardiovascular Dialysis Events (BLOCADE) Feasibility Study: A Randomized Controlled Trial. American Journal of Kidney Diseases, 2016, 67, 902-911.	1.9	36
41	The impact of social disadvantage in moderate-to-severe chronic kidney disease: an equity-focused systematic review*. Nephrology Dialysis Transplantation, 2016, 31, 46-56.	0.7	76
42	The Perspectives of Patients on Health-Care for Co-Morbid Diabetes and Chronic Kidney Disease: A Qualitative Study. PLoS ONE, 2016, 11, e0146615.	2.5	40
43	The Effect of a Cardiovascular Polypill Strategy on Pill Burden. Cardiovascular Therapeutics, 2015, 33, 347-352.	2.5	25
44	Facilitators and barriers to implementation of a pragmatic clinical trial in Aboriginal health services. Medical Journal of Australia, 2015, 203, 24-27.	1.7	13
45	Effect of a Computer-Guided, Quality Improvement Program for Cardiovascular Disease Risk Management in Primary Health Care. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 87-95.	2.2	98
46	Patient Preferences for a Polypill for the Prevention of Cardiovascular Diseases. Annals of Pharmacotherapy, 2015, 49, 528-539.	1.9	22
47	Research Priorities in CKD: Report of a National Workshop Conducted in Australia. American Journal of Kidney Diseases, 2015, 66, 212-222.	1.9	73
48	Hyperfiltration in Indigenous Australians with and without diabetes. Nephrology Dialysis Transplantation, 2015, 30, 1877-1884.	0.7	12
49	Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet, The, 2015, 385, 1975-1982.	13.7	1,522
50	Economic Evaluation of Neutral-pH, Low–Glucose Degradation Product Peritoneal Dialysis Solutions Compared With Standard Solutions: A Secondary Analysis of the balANZ Trial. American Journal of Kidney Diseases, 2015, 65, 773-779.	1.9	16
51	Adding Measures of Body Composition to the CKD-EPI GFR Estimating Equation in Indigenous Australians: The eGFR Study. American Journal of Kidney Diseases, 2015, 65, 632-634.	1.9	3
52	Community Preferences for the Allocation of Donor Organs for Transplantation. Transplantation, 2015, 99, 560-567.	1.0	23
53	Patients' and Providers' Perspectives of a Polypill Strategy to Improve Cardiovascular Prevention in Australian Primary Health Care. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 301-308.	2.2	29
54	The Effect of Exit-Site Antibacterial Honey versus Nasal Mupirocin Prophylaxis on the Microbiology and Outcomes of Peritoneal Dialysis-Associated Peritonitis and Exit-Site Infections: A Sub-Study of the Honeypot Trial. Peritoneal Dialysis International, 2015, 35, 712-721.	2.3	14

#	Article	IF	CITATIONS
55	A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. European Journal of Preventive Cardiology, 2015, 22, 920-930.	1.8	136
56	A Randomized, Placebo-Controlled Trial of Pentoxifylline on Erythropoiesis-Stimulating Agent Hyporesponsiveness in Anemic Patients With CKD: The Handling Erythropoietin Resistance With Oxpentifylline (HERO) Trial. American Journal of Kidney Diseases, 2015, 65, 49-57.	1.9	29
57	An economic case for a cardiovascular polypill? A cost analysis of the Kanyini GAP trial. Medical Journal of Australia, 2014, 201, 671-673.	1.7	18
58	COnsiderations of Nephrologists when Suggesting Dialysis in Elderly patients with Renal failure (CONSIDER): a discrete choice experiment. Nephrology Dialysis Transplantation, 2014, 29, 2302-2309.	0.7	26
59	Daily Protein Intake and Patient Outcomes in Severe Acute Kidney Injury: Findings of the Randomized Evaluation of Normal versus Augmented Level of Replacement Therapy (RENAL) Trial. Blood Purification, 2014, 37, 325-334.	1.8	25
60	Establishing a clinical trials network in nephrology: experience of the Australasian Kidney Trials Network. Kidney International, 2014, 85, 23-30.	5.2	17
61	How to advocate for the inclusion of chronic kidney disease in a national noncommunicable chronic disease program. Kidney International, 2014, 85, 1269-1274.	5.2	23
62	Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis. Nephrology Dialysis Transplantation, 2014, 29, 406-413.	0.7	191
63	Long-Term Survival and Dialysis Dependency Following Acute Kidney Injury in Intensive Care: Extended Follow-up of a Randomized Controlled Trial. PLoS Medicine, 2014, 11, e1001601.	8.4	117
64	What factors influence people's decisions to register for organ donation? The results of a nominal group study. Transplant International, 2014, 27, 617-624.	1.6	49
65	Performance of formulas for estimating glomerular filtration rate in Indigenous Australians with and without TypeÂ2 diabetes: the <scp>eGFR</scp> Study. Diabetic Medicine, 2014, 31, 829-838.	2.3	25
66	Effects of Lowering LDL Cholesterol on Progression of Kidney Disease. Journal of the American Society of Nephrology: JASN, 2014, 25, 1825-1833.	6.1	142
67	Timing of Renal Replacement Therapy and Patient Outcomes in the Randomized Evaluation of Normal Versus Augmented Level of Replacement Therapy Study*. Critical Care Medicine, 2014, 42, 1756-1765.	0.9	35
68	Antibacterial honey for the prevention of peritoneal-dialysis-related infections (HONEYPOT): a randomised trial. Lancet Infectious Diseases, The, 2014, 14, 23-30.	9.1	76
69	Impact of Estimated GFR Reporting on Late Referral Rates and Practice Patterns for End-Stage Kidney Disease Patients: A Multilevel Logistic Regression Analysis Using the Australia and New Zealand Dialysis and Transplant Registry (ANZDATA). American Journal of Kidney Diseases, 2014, 64, 359-366.	1.9	31
70	Choice of renal replacement therapy modality and dialysis dependence after acute kidney injury: a systematic review and meta-analysis. Intensive Care Medicine, 2013, 39, 987-997.	8.2	262
71	Early acid–base and blood pressure effects of continuous renal replacement therapy intensity in patients with metabolic acidosis. Intensive Care Medicine, 2013, 39, 429-436.	8.2	28
72	Prospective meta-analysis of trials comparing fixed dose combination based care with usual care in individuals at high cardiovascular risk: The SPACE Collaboration. International Journal of Cardiology, 2013, 170, 30-35.	1.7	29

#	Article	IF	Citations
73	Estimating the Total Incidence of Kidney Failure in Australia Including Individuals Who Are Not Treated by Dialysis or Transplantation. American Journal of Kidney Diseases, 2013, 61, 413-419.	1.9	54
74	Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis. European Heart Journal, 2013, 34, 1807-1817.	2.2	156
75	Rationing scarce organs for transplantation: healthcare provider perspectives on waitâ€listing and organ allocation. Clinical Transplantation, 2013, 27, 60-71.	1.6	21
76	Outcomes of Extended-Hours Hemodialysis Performed Predominantly at Home. American Journal of Kidney Diseases, 2013, 61, 247-253.	1.9	52
77	Tripterygium Preparations for the Treatment of CKD: A Systematic Review and Meta-analysis. American Journal of Kidney Diseases, 2013, 62, 515-530.	1.9	53
78	Strategies to improve adherence to medications for cardiovascular diseases in socioeconomically disadvantaged populations: A systematic review. International Journal of Cardiology, 2013, 167, 2430-2440.	1.7	36
79	Community preferences for the allocation of deceased donor organs for transplantation: a focus group study. Nephrology Dialysis Transplantation, 2013, 28, 2187-2193.	0.7	19
80	Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney International, 2013, 83, 517-523.	5.2	256
81	The IMPAKT study: using qualitative research to explore the impact of end-stage kidney disease and its treatments on aboriginal and Torres Strait Islander Australians. Kidney International Supplements, 2013, 3, 223-226.	14.2	14
82	The Honeypot Randomized Controlled Trial Statistical Analysis Plan. Peritoneal Dialysis International, 2013, 33, 426-435.	2.3	9
83	Prevention of Contrast-Induced AKI. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1618-1631.	4.5	94
84	Transplantation rates for living- but not deceased-donor kidneys vary with socioeconomic status in Australia. Kidney International, 2013, 83, 138-145.	5.2	51
85	Preoperative Estimates of Glomerular Filtration Rate as Predictors of Outcome after Surgery. Anesthesiology, 2013, 118, 809-824.	2.5	78
86	Survival of elderly dialysis patients is predicted by both patient and practice characteristics. Nephrology Dialysis Transplantation, 2012, 27, 3581-3587.	0.7	75
87	Factors that influence the decision to be an organ donor: a systematic review of the qualitative literature. Nephrology Dialysis Transplantation, 2012, 27, 2526-2533.	0.7	201
88	Cardiovascular risk management in chronic kidney disease in general practice (the AusHEART study). Nephrology Dialysis Transplantation, 2012, 27, 1396-1402.	0.7	42
89	Socio-economic status and incidence of renal replacement therapy: a registry study of Australian patients. Nephrology Dialysis Transplantation, 2012, 27, 4173-4180.	0.7	43
90	The risk of cancer in people with diabetes and chronic kidney disease. Nephrology Dialysis Transplantation, 2012, 27, 3337-3344.	0.7	31

#	Article	IF	Citations
91	Community Attitudes to Deceased Organ Donation. Transplantation, 2012, 93, 1064-1069.	1.0	38
92	An observational study fluid balance and patient outcomes in the randomized evaluation of normal vs. augmented level of replacement therapy trial*. Critical Care Medicine, 2012, 40, 1753-1760.	0.9	776
93	Hydroxyethyl Starch or Saline for Fluid Resuscitation in Intensive Care. New England Journal of Medicine, 2012, 367, 1901-1911.	27.0	1,460
94	Accurate Assessment of Kidney Function in Indigenous Australians: The Estimated GFR Study. American Journal of Kidney Diseases, 2012, 60, 680-682.	1.9	40
95	Prediction of Kidney-Related Outcomes in Patients With Type 2 Diabetes. American Journal of Kidney Diseases, 2012, 60, 770-778.	1.9	110
96	Challenges in Blood Pressure Measurement in Patients Treated With Maintenance Hemodialysis. American Journal of Kidney Diseases, 2012, 60, 463-472.	1.9	13
97	Effects of Fibrates in Kidney Disease. Journal of the American College of Cardiology, 2012, 60, 2061-2071.	2.8	148
98	Ten principles relevant to health research among Indigenous Australian populations. Medical Journal of Australia, 2012, 197, 16-18.	1.7	142
99	How fair is Medicare? The incomeâ€related distribution of Medicare benefits with special focus on chronic care items. Medical Journal of Australia, 2012, 197, 625-630.	1.7	8
100	Disparities between Prescribing of Secondary Prevention Therapies for Stroke and Coronary Artery Disease in General Practice. International Journal of Stroke, 2012, 7, 649-654.	5.9	20
101	Effects of Beta-Adrenergic Antagonists in Patients With Chronic Kidney Disease. Journal of the American College of Cardiology, 2011, 58, 1152-1161.	2.8	148
102	Physical inactivity and chronic kidney disease in Australian adults: The AusDiab study. Nutrition, Metabolism and Cardiovascular Diseases, 2011, 21, 104-112.	2.6	37
103	The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet, The, 2011, 377, 2181-2192.	13.7	2,087
104	New tools for an old trade: a socioâ€technical appraisal of how electronic decision support is used by primary care practitioners. Sociology of Health and Illness, 2011, 33, 1002-1018.	2.1	17
105	Nephrologists' Perspectives on Waitlisting and Allocation of Deceased Donor Kidneys for Transplant. American Journal of Kidney Diseases, 2011, 58, 704-716.	1.9	29
106	What determines adherence to treatment in cardiovascular disease prevention? Protocol for a mixed methods preference study. BMJ Open, 2011, 1, e000372-e000372.	1.9	14
107	Community Preferences for the Allocation of Solid Organs for Transplantation: A Systematic Review. Transplantation, 2010, 89, 796-805.	1.0	67
108	Patient Views About Treatment of Stage 5 CKD: A Qualitative Analysis of Semistructured Interviews. American Journal of Kidney Diseases, 2010, 55, 431-440.	1.9	62

#	Article	IF	CITATIONS
109	Cost-Effectiveness of Screening and Optimal Management for Diabetes, Hypertension, and Chronic Kidney Disease: A Modeled Analysis. Value in Health, 2010, 13, 196-208.	0.3	66
110	Robust data to close the gap: current vascular and maternal/newborn indicators as measures of progress in Aboriginal health in New South Wales. Australian and New Zealand Journal of Public Health, 2010, 34, 563-571.	1.8	2
111	Intensities of Renal Replacement Therapy in Acute Kidney Injury. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 956-963.	4.5	73
112	Long-Term Cancer Risk of Immunosuppressive Regimens after Kidney Transplantation. Journal of the American Society of Nephrology: JASN, 2010, 21, 852-858.	6.1	194
113	Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. European Heart Journal, 2010, 31, 2888-2896.	2.2	85
114	Aspirin Is Beneficial in Hypertensive Patients With Chronic Kidney Disease. Journal of the American College of Cardiology, 2010, 56, 956-965.	2.8	171
115	Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet, The, 2010, 375, 1875-1884.	13.7	788
116	Blood Pressure Is a Major Risk Factor for Renal Death. Hypertension, 2009, 54, 509-515.	2.7	50
117	Indigenous people in Australia, Canada, New Zealand and the United States are less likely to receive renal transplantation. Kidney International, 2009, 76, 659-664.	5.2	103
118	Intensity of Continuous Renal-Replacement Therapy in Critically Ill Patients. New England Journal of Medicine, 2009, 361, 1627-1638.	27.0	1,288